MARKET

ALBO

ALBO

Albireo Pharma Inc
NASDAQ
44.95
+0.40
+0.90%
After Hours: 44.95 0 0.00% 16:00 02/03 EST
OPEN
44.15
PREV CLOSE
44.55
HIGH
45.23
LOW
44.15
VOLUME
511.14K
TURNOVER
0
52 WEEK HIGH
45.23
52 WEEK LOW
16.02
MARKET CAP
930.52M
P/E (TTM)
-6.6882
1D
5D
1M
3M
1Y
5Y
Buyout From Ipsen: Do Not Underestimate The Value Of Albireo's Contingent Value Right
Seeking Alpha · 2d ago
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma
Seeking Alpha · 3d ago
Insider Sell: Albireo Pharma
Insider Sell: Albireo Pharma
MT Newswires · 01/20 16:16
Analysts move to downgrade Albireo Pharma after Ipsen's proposed acquisition
Seeking Alpha · 01/11 18:43
Cowen & Co. Downgrades Albireo Pharma: Here's What You Need To Know
Benzinga · 01/11 17:00
Guggenheim Downgrades Albireo Pharma to Neutral
Benzinga · 01/11 14:22
Expert Ratings for Albireo Pharma
Benzinga · 01/11 12:00
Cowen & Co. Downgrades Albireo Pharma to Market Perform, Lowers Price Target to $48
Benzinga · 01/11 09:54
More
About ALBO
Albireo Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its product, Bylvay, is for the treatment of pruritis in patients with progressive familial intrahepatic cholestasis (PFIC) ages three months or older and is authorized in Europe for the treatment of PFIC in patients ages six months or older. Its product candidate elobixibat is licensed for the treatment of chronic constipation and other functional diseases in Japan and other select markets in Asia. Its lead candidate for adult liver diseases, A3907, is a selective inhibitor of the apical sodium-dependent bile acid transporter (ASBT) where systemic bioavailability has been demonstrated in preclinical and clinical studies. Its preclinical candidate for adult viral and liver diseases includes A2342.

Webull offers kinds of Albireo Pharma Inc stock information, including NASDAQ:ALBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALBO stock methods without spending real money on the virtual paper trading platform.